Cetrorelix acetate (Cetrotide) is a powerful GnRH antagonist specifically designed to prevent premature ovulation in IVF patients. Its adaptable administration options enhance patient comfort while significantly reducing the risk of ovarian hyperstimulation syndrome (OHSS).
Mechanism
Cetrorelix works by competitively blocking GnRH receptors in the pituitary gland, swiftly inhibiting LH and FSH release without the initial stimulation caused by GnRH agonists. This rapid LH suppression is essential during ovarian stimulation phases, ensuring precise control during IVF cycles. Its unique structural modifications confer high affinity for receptors, facilitating pure antagonist action for optimal gonadotropin regulation.
Research
Clinical studies highlight that cetrorelix offers exceptional management of LH surges, boasting a mere 0.4% incidence of OHSS--significantly lower than alternative GnRH antagonists. This makes it especially valuable for patients with polycystic ovary syndrome (PCOS) or a history of OHSS.
Synergies
When combined with exogenous gonadotropins in IVF protocols, cetrorelix enhances follicular development and optimizes oocyte retrieval timing. Ben IQ assesses YOUR labs and goals to customize the best regimen for your success.
Trade-Offs
While cetrorelix presents notable benefits, it tends to be pricier than other alternatives and requires reconstitution prior to use. Keep in mind, each scenario is unique, and YOUR data is key for the best outcome.